Follow
← Back
Medicines · Interactions

Imatinib — interactions

Other medicines, foods and herbal products can change how Imatinib works. Everything on this page comes from Imatinib's own FDA-approved label — the same source as the main guide.

← Back to the full Imatinib guide

⚠ Caution: CYP3A4 inducers may decrease imatinib mesylate C max and area under curve (AUC). CYP3A4 inhibitors may increase imatinib mesylate C max and AUC. Imatinib mesylate is an inhibitor of CYP3A4 and CYP2D6 which may increase the C max and AUC of other drugs. Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin.

Medicines named in Imatinib's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Agents Inducing CYP3A Metabolism

Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents .

Agents Inhibiting CYP3A Metabolism

Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase. Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice .

Section 7.3 of the label

Interactions With Drugs Metabolized by CYP3A4 Imatinib mesylate will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering imatinib mesylate tablets with CYP3A4 substrates that have a narrow therapeutic window.

Section 7.4 of the label

Interactions With Drugs Metabolized by CYP2D6 Use caution when administering imatinib mesylate with CYP2D6 substrates that have a narrow therapeutic window.

Interactions With Methotrexate

Imatinib mesylate tablets may delay the clearance of methotrexate and result in sustained methotrexate concentrations when methotrexate is used at high doses (>500 mg/m 2 ). Refer to the prescribing information for methotrexate injection for recommendations on management of methotrexate concentrations.

Imatinib's label names 4 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Imatinib's label have interaction pages of their own:

Food, drink & herbs in the label

Grapefruit

Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice .

Read the full interactions section from Imatinib's label

CYP3A4 inducers may decrease imatinib mesylate C max and area under curve (AUC). CYP3A4 inhibitors may increase imatinib mesylate C max and AUC. Imatinib mesylate is an inhibitor of CYP3A4 and CYP2D6 which may increase the C max and AUC of other drugs. Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin. Imatinib mesylate tablets delay the clearance of methotrexate when methotrexate is used at high doses (> 500 mg/m 2 ).

7.1 Agents Inducing CYP3A Metabolism Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents .

7.2 Agents Inhibiting CYP3A Metabolism Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase. Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice .

7.3 Interactions With Drugs Metabolized by CYP3A4 Imatinib mesylate will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering imatinib mesylate tablets with CYP3A4 substrates that have a narrow therapeutic window. Because warfarin is metabolized by CYP2C9 and CYP3A4, use low-molecular weight or standard heparin instead of warfarin in patients who require anticoagulation .

7.4 Interactions With Drugs Metabolized by CYP2D6 Use caution when administering imatinib mesylate with CYP2D6 substrates that have a narrow therapeutic window.

7.5 Interactions With Methotrexate Imatinib mesylate tablets may delay the clearance of methotrexate and result in sustained methotrexate concentrations when methotrexate is used at high doses (>500 mg/m 2 ). Refer to the prescribing information for methotrexate injection for recommendations on management of methotrexate concentrations.

Imatinib guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 8 Sep 2026) · National List of Essential Medicines, Nepal (2021) · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Imatinib's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.
.textContent=pill.getAttribute('data-copied');pill.style.borderColor='#14855f';pill.style.color='#14855f';pill.style.background='#eafaf3';setTimeout(function(){pill.textContent=orig;pill.style.borderColor='';pill.style.color='';pill.style.background=''},2000)})});})();